California Public Employees Retirement System Has $175.91 Million Stake in CVS Health Corporation $CVS

California Public Employees Retirement System increased its stake in CVS Health Corporation (NYSE:CVS) by 5.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,333,350 shares of the pharmacy operator’s stock after purchasing an additional 123,846 shares during the period. California Public Employees Retirement System owned approximately 0.18% of CVS Health worth $175,911,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. lifted its holdings in shares of CVS Health by 72.1% in the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 142 shares in the last quarter. Corundum Trust Company INC acquired a new position in shares of CVS Health during the third quarter worth about $29,000. Front Row Advisors LLC grew its holdings in shares of CVS Health by 436.5% during the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock worth $31,000 after buying an additional 371 shares in the last quarter. SOA Wealth Advisors LLC. raised its position in CVS Health by 36.9% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock valued at $37,000 after buying an additional 131 shares during the last quarter. Finally, Twin Peaks Wealth Advisors LLC bought a new stake in CVS Health in the 2nd quarter valued at approximately $36,000. Institutional investors own 80.66% of the company’s stock.

CVS Health Trading Up 0.1%

NYSE CVS opened at $76.14 on Monday. CVS Health Corporation has a 12 month low of $58.35 and a 12 month high of $85.15. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The stock has a 50 day moving average of $78.17 and a 200-day moving average of $77.83. The company has a market cap of $96.87 billion, a PE ratio of 55.17, a PEG ratio of 0.79 and a beta of 0.49.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. The firm had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, equities research analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.5%. The ex-dividend date was Thursday, January 22nd. CVS Health’s dividend payout ratio (DPR) is 192.75%.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” with a $94 price target, signaling upward analyst momentum and providing a clear catalyst for investor sentiment. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced a new AI-powered health platform, which could boost growth prospects for care management, digital engagement and margin improvement if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause accredited, strengthening its clinical services and retail clinic positioning in women’s health — a niche revenue/traffic driver over time. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are revising fair‑value estimates modestly (one update moved fair value ~US$94→US$96), reflecting balanced views: upside from Medicare Advantage exposure but uncertainty on managed‑care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Competitive dynamics: a North Carolina health plan is triggering a bidding fight for 2028 Aetna/CVS contracts — potential upside if CVS wins, but outcome uncertain. N.C. Health Plan Sparks 2028 Bidding War Over Aetna And CVS Contracts
• Neutral Sentiment: Market reaction since earnings: commentary and data pieces note the stock has moved modestly since last quarter; investors are parsing guidance and EPS trajectory for cues. Why Is CVS Health (CVS) Down 1.7% Since Last Earnings Report?
• Negative Sentiment: Aetna, a CVS subsidiary, agreed to a $117.7M DOJ settlement over alleged inaccurate diagnosis coding in Medicare Advantage — a material legal headline that keeps compliance and MA reimbursement risk on investors’ radar. Aetna’s US$117.7m Settlement Puts CVS Health Compliance In Focus
• Negative Sentiment: Policy risk: CVS warned it may close 100+ Tennessee pharmacies if proposed PBM legislation passes, highlighting state‑level regulatory risk that could reduce retail footprint and revenues in affected markets. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

Analyst Upgrades and Downgrades

CVS has been the subject of several research reports. Bank of America decreased their price target on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research note on Tuesday, January 27th. Truist Financial set a $100.00 target price on shares of CVS Health in a report on Wednesday, December 10th. The Goldman Sachs Group raised their target price on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. Morgan Stanley lifted their price target on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Finally, Sanford C. Bernstein upgraded shares of CVS Health from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $91.00 to $94.00 in a research note on Thursday. Twenty analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $95.05.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.